EGFR and non-small cell lung carcinoma: In a retrospective efficacy analysis of PD-1 inhibitors conducted by a Japanese group, NSCLC patients harboring uncommon EGFR mutations and without T790M mutations were associated with significantly longer PFS than those with common EGFR mutations or with T790M mutation (97).